promo_leaderboard Ad
‹ All stocks
KOD

Kodiak Sciences

KOD · NASDAQ · Healthcare
$99.96
▼ $0.77 (-0.76%)
$85.08 $93.78 $102.49 $111.19 $99.96 Oct 18 Nov 02 Nov 17
Day range
$98.30 – $104.36
Year range
$18.15 – $112.79
Open
$101.74
Previous close
$100.73
Market cap
$6.54B
Volume (24h)
$52.0K
Volume (52w)
$5.20M
Performance
7D
▼ -7.50%
1M
▲ 9.43%
3M
▲ 149.46%
6M
▲ 167.20%
1Y
▲ 404.09%
YTD
▲ 284.17%
3Y
▲ 4013.58%
5Y
▲ 396.57%
All-time
▲ 4824.14%
Key statistics
P/E ratio
-24.50
EPS (TTM)
$-4.08
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
65.4M
About Kodiak Sciences

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Visit website
Country: United States of America
Related news
More in Healthcare